Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Emerging targets for the treatment of lung cancer

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 26.07.17
Views: 2445

Prof Tarek Mekhail - Florida Hospital Cancer Institute, Orlando, USA

Prof Mekhail speaks with ecancer at NOSCM 2017 targeted therapies for lung cancer.

He looks beyond EGFR and ALK mutations to emerging targets in lung cancer including BRAF and HER2, which have significant histories in other disease but are now becoming apparent as lung cancer drivers, and rearrangements in MET and RET genes.

Prof Mekhail also discusses immune evasion of tumours, and how immunotherapies can reawaken immune cells to clear cancer cells.

Targeted therapy for lung cancer was also discussed at NOSCM 2017 by Dr Luis Raez, here, and at the 2017 WIN symposium by Dr Reinhard Büttner, here.

Related videos

follow us

ONJ e-learning

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

Cancer Intelligence